01—Abstract
Summary
Summary of the 8-K filed September 14, 2026. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) filed a Form 8-K on September 14, 2026 to report an executive promotion.
The Board appointed Jereme Sylvain, the Company's Executive Vice President and Chief Financial Officer, to the additional role of Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. Under the Offer Letter signed September 11, 2026, Mr. Sylvain's annual base salary is $767,000,a with an annual target bonus of 75% of base salary. He remains eligible for annual equity awards under the Amended and Restated 2015 Equity Incentive Plan and participates in the Severance & Change in Control Plan as an executive officer.
The filing does not disclose any new equity grants, sign-on payments, or changes to his compensation beyond the stated base and target bonus. In the expanded role, Mr. Sylvain will oversee Dexcom's global operations and quality teams, per the accompanying press release (Exhibit 99.1). CEO Jake Leach described the move as a way to scale the company more effectively.
Mr. Sylvain has been with Dexcom since 2018 and has served as CFO since 2021. Consolidating operations and quality oversight with finance under one executive is a notable organizational change, and it signals management's focus on execution and margin discipline as the company pursues growth. The filing is largely administrative and contains no quantitative financial results, guidance, or changes to the company's reported financial position.
Investors may watch for whether Dexcom names a new CFO or restructures reporting lines, and whether the operational scope affects execution on product, manufacturing, or quality matters. The full Offer Letter will be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026.
02—Key points
Key Highlights
- Jereme Sylvain, EVP and CFO since 2021, was promoted to EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.
- Base salary set at $767,000 with an annual target bonus of 75% of base salary under the September 11, 2026 Offer Letter.
- Expanded remit includes oversight of Dexcom's global operations and quality teams, per the press release.
- Mr. Sylvain remains eligible for annual equity awards under the Amended and Restated 2015 Equity Incentive Plan and participates in the Severance & Change in Control Plan as an executive officer.
- Dexcom's CEO Jake Leach characterized the promotion as supporting the company's ability to scale more effectively toward its growth goals.
- The filing contains no new financial results, guidance, or disclosed changes to Dexcom's financial position.
- The full Offer Letter will be filed with the Form 10-Q for the quarter ended September 30, 2026.
03—Questions
Frequently Asked Questions
Who is being promoted and what are the new titles?
Jereme Sylvain, who has been Dexcom's Executive Vice President and Chief Financial Officer, was appointed Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. He keeps the CFO role and adds the COO responsibilities.
What is Mr. Sylvain's compensation under the new arrangement?
Under the Offer Letter dated September 11, 2026, he receives an annual base salary of $767,000 and an annual target bonus of 75% of base salary. The filing does not disclose new equity grants or sign-on payments, though he remains eligible for annual equity awards under the 2015 Equity Incentive Plan.
What responsibilities does the COO role add?
According to the press release, Mr. Sylvain will oversee Dexcom's global operations and quality teams, with the stated aim of greater alignment, speed, and accountability in executing the company's growth and operational excellence goals.
Does this announcement change Dexcom's financial outlook?
No. The 8-K contains no financial results, guidance, or updated financial metrics. It is an executive appointment and compensation disclosure.
Where can investors find the full terms of the Offer Letter?
The Offer Letter is not attached to this 8-K. Dexcom states it will be filed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
04—Continue